Connection
Frederick Masoudi to Proprotein Convertase 9
This is a "connection" page, showing publications Frederick Masoudi has written about Proprotein Convertase 9.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.066 |
|
|
|
-
Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
Score: 0.033
-
Hess PL, Kennedy K, Cowherd M, Virani SS, Masoudi FA, Navar AM, Yeh RW, Ho PM, Maddox TM. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
Score: 0.032